Welcome to our dedicated page for Cogent Biosciences news (Ticker: COGT), a resource for investors and traders seeking the latest updates and insights on Cogent Biosciences stock.
Cogent Biosciences develops precision therapies for genetically defined diseases, with recurring updates centered on bezuclastinib and KIT-driven disorders including Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST). News commonly covers bezuclastinib clinical data from the SUMMIT and PEAK programs, U.S. FDA New Drug Application activity, medical-meeting presentations and related business updates.
Company announcements also describe preclinical oncology programs such as CGT1263, a KRAS inhibitor candidate, and CGT4255, a brain-penetrant ErbB2/HER2 inhibitor candidate. Financial-result releases and capital updates address cash resources, at-the-market equity activity and Nasdaq inducement equity awards.
Cogent Biosciences (Nasdaq: COGT) presented updated preclinical data for its pan KRAS(ON) program at the 2025 AACR-NCI-EORTC conference on Oct 24, 2025. The poster describes CGT1263, a KRAS inhibitor with reported picomolar activity across KRAS mutant cell lines and selectivity over HRAS and NRAS. The company also detailed CGT1815, a prodrug designed to optimize human pharmacokinetics with supporting multi‑species PK data. Cogent says CGT1815 showed superior tumor growth inhibition versus RMC-6236 in KRASG12D and KRASG12V preclinical models, and the company aims to file an IND in 2026.
Cogent Biosciences (Nasdaq: COGT) announced the FDA granted Breakthrough Therapy Designation for bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) previously treated with avapritinib and in Smoldering Systemic Mastocytosis.
The designation is based on positive SUMMIT results showing statistical significance across all primary and key secondary endpoints; top-line SUMMIT data were reported in July 2025 and additional data will be presented at a scientific conference. Cogent completed a pre-NDA meeting and plans an NDA submission by year-end 2025, with Breakthrough benefits including Priority Review eligibility and rolling submissions.
Cogent also plans top-line reads for the Phase 3 PEAK trial in GIST in November 2025 and for the APEX trial in AdvSM in December 2025.
Cogent Biosciences (Nasdaq: COGT), a biotechnology company specializing in precision therapies, has granted inducement equity awards to 10 new employees. The Compensation Committee approved options to purchase 299,200 shares of common stock under the company's 2020 Inducement Plan on September 29, 2025.
The options feature a 10-year term with a four-year vesting schedule, including 25% vesting after one year and the remainder vesting monthly over 36 months. The exercise price equals Cogent's closing stock price on the grant date, subject to continued employment through vesting dates.
Cogent Biosciences (Nasdaq: COGT), a biotechnology company developing precision therapies, announced its participation in the Citi Biopharma Back to School Conference on September 3, 2025 at 9:00 a.m. ET. A live webcast will be available on the company's investor relations website, with a replay accessible for 30 days.
Additionally, the company granted inducement equity awards to two new employees, consisting of options to purchase 54,500 shares of common stock. The options have a 10-year term and a four-year vesting schedule, with 25% vesting after one year and the remainder monthly over 36 months.
Cogent Biosciences (NASDAQ: COGT) reported significant achievements in Q2 2025, highlighted by positive top-line results from the SUMMIT trial evaluating bezuclastinib in NonAdvanced Systemic Mastocytosis. The trial met its primary endpoint with a statistically significant improvement in Total Symptom Score (24.3-point reduction vs. 15.4 points for placebo, p=0.0002).
The company strengthened its financial position through two major transactions: a $400 million debt facility with SLR Capital Partners and an upsized $230 million public offering. With $453 million in pro-forma cash, Cogent is funded through anticipated launch and into 2027. Q2 2025 resulted in a net loss of $73.5 million, with R&D expenses of $62.2 million.
Key upcoming catalysts include pivotal trial results from PEAK (GIST) and APEX (AdvSM) trials in 2H 2025, followed by the company's first NDA submission by year-end.
Cogent Biosciences (NASDAQ: COGT) has successfully closed its upsized public offering of 25,555,556 shares of common stock at $9.00 per share, including the full exercise of underwriters' option to purchase additional shares. The offering generated approximately $230 million in gross proceeds before deducting expenses.
The biotechnology company, focused on precision therapies for genetically defined diseases, plans to use the proceeds for development and commercial preparation of bezuclastinib and other product candidates. J.P. Morgan, Leerink Partners, and Guggenheim Securities served as joint book-running managers, with LifeSci Capital acting as lead manager.
Cogent Biosciences (NASDAQ: COGT) has announced the pricing of its upsized public offering of 22,222,223 shares of common stock at $9.00 per share, expecting to raise approximately $200 million in gross proceeds.
The offering includes a 30-day option for underwriters to purchase up to an additional 3,333,333 shares under the same terms. The company plans to use the proceeds for bezuclastinib development, regulatory and commercial preparation activities, and general corporate purposes. The offering is expected to close around July 10, 2025.
J.P. Morgan, Leerink Partners, and Guggenheim Securities are serving as joint book-running managers, with LifeSci Capital acting as lead manager for the offering.
Cogent Biosciences (NASDAQ: COGT), a biotechnology company specializing in precision therapies, has announced a proposed $150 million public offering of common stock. The company will also grant underwriters a 30-day option to purchase up to an additional $22.5 million of shares.
The proceeds will fund the development and commercial preparation of bezuclastinib and other product candidates, support bezuclastinib's planned commercial launch, and provide working capital. J.P. Morgan, Leerink Partners, and Guggenheim Securities are serving as joint book-running managers, with LifeSci Capital as lead manager.
Cogent Biosciences (NASDAQ: COGT) announced breakthrough results from its SUMMIT trial evaluating bezuclastinib in non-advanced systemic mastocytosis patients. The drug achieved statistical significance across all primary and secondary endpoints, demonstrating a superior mean change in total symptom score of -24.3 points versus -15.4 for placebo (p=0.0002).
Key highlights include 87.4% of treated patients achieving ≥50% reduction in serum tryptase compared to 0% for placebo. The drug showed a favorable safety profile with mostly low-grade adverse events. The company plans to submit an NDA to FDA by end of 2025, supported by a strong financial position of $237 million cash and access to $350 million in debt facility.
Additionally, Cogent expects to share results from pivotal trials PEAK (GIST) and APEX (AdvSM) in 2H 2025.